What drove TEVA's earnings growth in 2024?

Teva Pharmaceutical Industries (TEVA) experienced earnings growth in 2024 primarily driven by strong revenue performance across its business segments: 1. **Revenue Growth**: Teva's revenue increased by 7.4% in Q2 2024, reaching $4.16 billion, up from $3.82 billion in Q1 2024. This growth was fueled by a 14% increase in the Generics Business and a 5% increase in the TAPI API segment. The company's innovative products, such as Austedo and Ajovy, also contributed significantly, with Austedo experiencing a 32% growth and Ajovy growing by 21%. 2. **International Markets**: The International Markets segment showed notable growth, with a 7.4% increase in revenue. This was supported by Teva's expansion in emerging markets and a strong performance in Europe. 3. **Licensing Arrangements**: Licensing Arrangements segment contributed positively to the revenue growth, although specific figures are not available. 4. **Cost Management**: Teva's cost management efforts, including a focus on reducing operating expenses and improving operational efficiencies, likely contributed to the improved profitability despite the net loss reported in Q2 2024. 5. **Market Strategy**: Teva's strategic focus on generics and biosimilars, coupled with the launch of new products, has positioned it well in the market. The company's pipeline progress, including the launch of biosimilars and advancements in innovative treatments, has likely supported its revenue growth. In summary, Teva's earnings growth in 2024 was driven by robust revenue performance across various segments, strategic market positioning, and effective cost management.